Werewolf Therapeutics Ownership
| HOWL Stock | USD 1.28 0.06 4.48% |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Werewolf |
Werewolf Stock Ownership Analysis
About 64.0% of the company shares are owned by institutional investors. The company has price-to-book (P/B) ratio of 0.64. Some equities with similar Price to Book (P/B) outperform the market in the long run. Werewolf Therapeutics recorded a loss per share of 1.52. The entity had not issued any dividends in recent years. Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the bodys immune system for the treatment of cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Cambridge, Massachusetts. Werewolf Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 47 people. To learn more about Werewolf Therapeutics call Daniel Hicklin at 617 952 0555 or check out https://werewolftx.com.Besides selling stocks to institutional investors, Werewolf Therapeutics also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Werewolf Therapeutics' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Werewolf Therapeutics' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Werewolf Therapeutics Quarterly Liabilities And Stockholders Equity |
|
About 6.0% of Werewolf Therapeutics are currently held by insiders. Unlike Werewolf Therapeutics' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Werewolf Therapeutics' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Werewolf Therapeutics' insider trades
Werewolf Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Werewolf Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Werewolf Therapeutics backward and forwards among themselves. Werewolf Therapeutics' institutional investor refers to the entity that pools money to purchase Werewolf Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Dc Funds, Lp | 2024-12-31 | 589.1 K | State Street Corp | 2024-12-31 | 426.8 K | Northern Trust Corp | 2024-12-31 | 244.4 K | Alyeska Investment Group, L.p. | 2024-12-31 | 235.7 K | Dimensional Fund Advisors, Inc. | 2024-12-31 | 194.7 K | Goldman Sachs Group Inc | 2024-12-31 | 141.8 K | Two Sigma Advisers, Llc | 2024-12-31 | 139.1 K | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 138.1 K | Bridgeway Capital Management, Llc | 2024-12-31 | 109.6 K | Ra Capital Management, Llc | 2024-12-31 | 6.1 M | Mpm Asset Management, Llc | 2024-12-31 | 4.3 M |
Werewolf Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Werewolf Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Werewolf Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Werewolf Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Werewolf Therapeutics Outstanding Bonds
Werewolf Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Werewolf Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Werewolf bonds can be classified according to their maturity, which is the date when Werewolf Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Werewolf Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in housing. For more information on how to buy Werewolf Stock please use our How to buy in Werewolf Stock guide.You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Werewolf Therapeutics. If investors know Werewolf will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Werewolf Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.52) | Revenue Per Share | Quarterly Revenue Growth (0.86) | Return On Assets | Return On Equity |
The market value of Werewolf Therapeutics is measured differently than its book value, which is the value of Werewolf that is recorded on the company's balance sheet. Investors also form their own opinion of Werewolf Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Werewolf Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Werewolf Therapeutics' market value can be influenced by many factors that don't directly affect Werewolf Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Werewolf Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Werewolf Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Werewolf Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.